Plasma half-life comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Drugs and sexual desire is about sexual desire being manipulated through drugs from various approaches. Sexual desire is generated under the effects from sex hormones and microcircuits from brain regions. Neurotransmitters play essential roles in stimulating and inhibiting the processes that lead to libido production in both men and women. For instance, a positive stimulation is modulated by dopamine from the medial preoptic area in the hypothalamus and norepinephrine. At the same time, inhibition occurs when prolactin and serotonin are released for action. Drugs acting on the above neurotransmitters can be used to upregulate or downregulate sexual desire due to diseased conditions. During drug development specialized for women, the Female Sexual Function Index-Desire Domain (FSFI-D) provides a reference measurement for researchers to evaluate recipients' responses and results. FSFI values allow researchers to monitor the change of sexual desire with a more solid definition, and at the same time, establish records for the U.S. Food and Drug Administration (FDA) to process applications for drug approval. Similarly, the Male Desire Scale (MDS) is used for men. After evaluating symptom severity using the scales, patients are then prescribed different types of drugs. Flibanserin and bremelanotide were developed for raising sexual desire in women, whereas similar conditions in men are treated using medications for sexual dysfunction. On the other hand, down-regulation on libido comes in two approaches: a direct or an indirect mechanism.
Finally, as cold seeps become inactive, tubeworms also start to disappear, clearing the way for corals to settle on the now-exposed carbonate substrate. The corals do not rely on hydrocarbons seeping out of the seafloor. Studies on Lophelia pertusa suggest they derive their nutrition primarily from the ocean surface. Chemosynthesis plays only a very small role, if any, in their settlement and growth. While deepwater corals do not seem to be chemosynthesis-based organisms, the chemosynthetic organisms that come before them enable the corals' existence. This hypothesis about establishment of deep water coral reefs is called hydraulic theory.
Manchester's Revolutionary 2D Material at The University of Manchester Graphene at The Periodic Table of Videos (University of Nottingham) Graphene: Patent surge reveals global race 'Engineering Controls for Nano-scale Graphene Platelets During Manufacturing and Handling Processes' (PDF) Band structure of graphene (PDF).
=== Viral infections === Increased blood CRP levels were higher in people with avian flu H7N9 compared to those with H1N1 (more common) influenza, with a review reporting that severe H1N1 influenza had elevated CRP. In 2020, people infected with COVID-19 in Wuhan, China, had elevated CRP.
== Nomenclature == Currently, no widespread and systematic nomenclature is used to differentiate pyoverdine structures. A system was proposed in 1989, consisting of Pyoverdine Type I, Type IIa, Type IIb, and Type III. At the time, only a few pyoverdine structures were known, and it was anticipated that much less variation would occur than has been seen. As a consequence of the tremendous heterogeneity observed in the peptide backbone, and the observation of congeners (pyoverdines from a single strain differing only in their ketoacid portions), nomenclature of pyoverdines remains rather tenuous and no single system has garnered universal acceptance.
Sources: en.wikipedia.org
=== Regulation of cell adhesion, migration, and survival === The α1β1 Integrin receptor binds collagens in the ECM and connects the α1β1 integrin complex to f-actin through the cytoplasmic tails of the integrin's recruitment of focal adhesion adaptor proteins (Talin, Kindlin, Paxillin, Vinculin, A-Actinin) which connects ECM to the actin cytoskeleton inside cells. This helps cells stick to and move throughout tissues. The interactions Integrin Alpha-1 has with the extracellular matrix promotes cell adhesion, migration, survival, and metastasis. In Pancreatic Ductal Adenocarcinoma (PDAC), ITGA1 promotes tumor cell adhesion and migration on collagen substrates. Loss of ITGA1 reduces collagen-dependent attachment, spreading, and cellular viability, demonstrating that ITGA1 functions as a receptor linking ECM composition to cellular behavior. ITGA1 also supports survival of aggressive tumor cell populations. In PDAC, ITGA1 identifies ALDH1-high stem-like cancer cells and contributes to the maintenance and viability of tumor-initiating populations. Reduction of ITGA1 decreases survival of ALDH1-high cells, which suggests that ITGA1 regulates pathways involved in tumor cell persistence and stem-like properties.
== Treatment == For patients with VWD type 1 and VWD type 2A, desmopressin is available as different preparations, recommended for use in cases of trauma, or in preparation for dental or surgical procedures. Desmopressin stimulates the release of VWF from the Weibel–Palade bodies of endothelial cells, thereby increasing the levels of VWF (as well as coagulant factor VIII) three- to five-fold. Desmopressin is also available as a preparation for intranasal administration (Stimate) and as a preparation for intravenous administration. Desmopressin is contraindicated in VWD type 2b because of the risk of aggravated thrombocytopenia and thrombotic complications. Desmopressin is probably not effective in VWD type 2M and is rarely effective in VWD type 2N. It is totally ineffective in VWD type 3. Regular preventative infusions of desmopressin to keep vWF levels normal (outside of planned surgical procedures or trauma) is not recommended. However, in very small limited studies, preventative desmopressin infusions have been shown to prevent bleeding episodes in severe VWD. For women with heavy menstrual bleeding, estrogen-containing oral contraceptive medications are effective in reducing the frequency and duration of the menstrual periods. Estrogen and progesterone compounds available for use in the correction of menorrhagia include ethinylestradiol, levonorgestrel, drospirenone and cyproterone.
== Metal sulfides == Sulfur reacts with many metals. Electropositive metals give polysulfide salts. Copper, zinc and silver are tarnished by sulfur. Although many metal sulfides are known, most are prepared by high temperature reactions of the elements. Sulfide minerals contain the sulfide (S2-) or disulfide (S22-) anions. Typical examples are:
== Clinical pharmacology == Although the drugs omeprazole, lansoprazole, pantoprazole, and rabeprazole share common structure and mode of action, each differs somewhat in its clinical pharmacology. Differing pyridine and benzimidazole substituents result in small, but potentially significant different physical and chemical properties. Direct comparison of pantoprazole sodium with other anti-secretory drugs showed that it was significantly more effective than H2-receptor antagonists and either equivalent or better than other clinically used PPIs. Another study states rabeprazole undergoes activation over a greater pH range than omeprazole, lansoprazole, and pantoprazole, and converts to the sulphenamide form more rapidly than any of these three drugs. Most oral PPI preparations are enteric-coated, due to the rapid degradation of the drugs in the acidic conditions of the stomach. For example omeprazole is unstable in acid with a half-life of 2 min at pH 1–3, but is significantly more stable at pH 7 (half-life ca. 20 h). The acid protective coating prevents conversion to the active principle in the lumen of the stomach, which then will react with any available sulfhydryl group in food and will not penetrate to the lumen of the secretory canaliculus The oral bioavailability of PPIs is high; 77% for pantoprazole, 80–90% for lansoprazole and 89% for esomeprazole. All the PPIs except tenatoprazole are rapidly metabolized in the liver by CYP enzymes, mostly by CYP2C19 and CYP3A4. PPIs are sensitive to CYP enzymes and have different pharmacokinetic profiles.
=== Procedures === Section 316 of the Criminal Procedure Code states that the death penalty in Singapore is to be conducted by hanging. Judicial hangings always take place shortly before dawn on a Friday and are conducted by the long drop method. The Singapore government has affirmed its choice of execution by hanging in favour of other methods. It is a normal practice for everyone present in the courtroom to stand and remain silent before the death sentence is passed. The judge will then proceed to announce the death sentence on the accused, who has been found guilty and convicted of the capital offence. The condemned will be given notice at least four days before execution. In the case of foreigners sentenced to death, their families and diplomatic missions or embassies will be given one to two weeks' notice.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.